Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
Felip, E., Altorki, N., Zhou, C., Vallières, E., Martínez-Martí, A., Rittmeyer, A., Chella, A., Reck, M., Goloborodko, O., Huang, M., Belleli, R., McNally, V., Srivastava, M.K., Bennett, E., Gitlitz, B.J., Wakelee, H.A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
Carter, C.A., Rajan, A., Keen, C., Szabo, E., Khozin, S., Thomas, A., Brzezniak, C., Guha, U., Doyle, L.A., Steinberg, S.M., Xi, L., Raffeld, M., Tomita, Y., Lee, M.J., Lee, S., Trepel, J.B., Reckamp, K.L., Koehler, S., Gitlitz, B., Salgia, R., Gandara, D., Vokes, E., Giaccone, G.
Published in Annals of oncology (01.04.2016)
Published in Annals of oncology (01.04.2016)
Get full text
Journal Article
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
ZISMAN, Amnon, PANTUCK, Allan J, DOREY, Fredrick, SAID, Jonathan W, SHVARTS, Oleg, QUINTANA, Deanna, GITLITZ, Barbara J, DEKERNION, Jean B, FIGLIN, Robert A, BELLDEGRUN, Arie S
Published in Journal of clinical oncology (15.03.2001)
Published in Journal of clinical oncology (15.03.2001)
Get full text
Journal Article
IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy
Peters, S., Kim, A.W., Solomon, B., Gandara, D.R., Dziadziuszko, R., Brunelli, A., Garassino, M.C., Reck, M., Wang, L., To, I., Sun, S.W., Gitlitz, B.J., Sandler, A., Rizvi, N.
Published in Annals of oncology (01.04.2019)
Published in Annals of oncology (01.04.2019)
Get full text
Journal Article
A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)
El-Khoueiry, A, Gitlitz, B, Cole, S, Tsao-Wei, D, Goldkorn, A, Quinn, D, Lenz, H.J, Nieva, J, Dorff, T, Oswald, M, Berg, J, Menendez, X, Karakozian, K, Krasnoperov, V, Liu, R, Thomas, J, Groshen, S, Gill, P
Published in European journal of cancer (1990) (01.12.2016)
Published in European journal of cancer (1990) (01.12.2016)
Get full text
Journal Article
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
Chew, H.K., Somlo, G., Mack, P.C., Gitlitz, B., Gandour-Edwards, R., Christensen, S., Linden, H., Solis, L.J., Yang, X., Davies, A.M.
Published in Annals of oncology (01.04.2012)
Published in Annals of oncology (01.04.2012)
Get full text
Journal Article
9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes
Hughes, B, Mileshkin, L, Townley, P, Gitlitz, B, Eaton, K, Mitchell, P, Hicks, R, Loecke, D, Amler, L, Pirzkall, A
Published in European journal of cancer (1990) (2011)
Published in European journal of cancer (1990) (2011)
Get full text
Journal Article
Adoptive cellular therapy
Hoffman, D M, Gitlitz, B J, Belldegrun, A, Figlin, R A
Published in Seminars in oncology (01.04.2000)
Get more information
Published in Seminars in oncology (01.04.2000)
Journal Article
Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells
Tso, C L, McBride, W H, Sun, J, Patel, B, Tsui, K H, Paik, S H, Gitlitz, B, Caliliw, R, van Ophoven, A, Wu, L, deKernion, J, Belldegrun, A
Published in The cancer journal (Sudbury, Mass.) (01.07.2000)
Get more information
Published in The cancer journal (Sudbury, Mass.) (01.07.2000)
Journal Article
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma
Gitlitz, Barbara J., Baker, Carole, Chapman, Yvonne, Allen, Heather J., Bosserman, Linda D., Patel, Ravi, Sanchez, James D., Shapiro, Richard M., Figlin, Robert A.
Published in Cancer (01.11.2003)
Published in Cancer (01.11.2003)
Get full text
Journal Article
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome
Zisman, A, Pantuck, A J, Chao, D, Dorey, F, Said, J W, Gitlitz, B J, de Kernion, J B, Figlin, R A, Belldegrun, A S
Published in The Journal of urology (01.07.2001)
Published in The Journal of urology (01.07.2001)
Get more information
Journal Article
OA13.06 The Epidemiology of Young Lung Cancer: Interim Analysis of Risk Factors and Genetic Mutations
Bittoni, M., Harper, A., Wu, A., Florez, N., King, J., Erwin, R., Addario, B., Carbone, D., Gitlitz, B., Nieva, J.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
EP11.02-06 Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS
Lee, S.M., Han, B., Peters, S., Le, A.T., Huang, D., Wu, G., Cao, L., Pham, C.P., Zhao, J., Wang, K., Yang, N., Zhong, H., Hu, Y., Morris, S., Lam, V., Graupner, V., Gitlitz, B., Hoglander, E., Schulz, C.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Zhou, C., Das Thakur, M., Srivastava, M.K., Zou, W., Xu, H., Ballinger, M., Felip, E., Wakelee, H., Altorki, N.K., Reck, M., Liersch, R., Kryzhanivska, A., Harada, M., Tanaka, H., Hamm, J., McCune, S., McNally, V., Bennett, E., Gitlitz, B., Novello, S.
Published in Annals of oncology (01.12.2021)
Published in Annals of oncology (01.12.2021)
Get full text
Journal Article
LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
Felip, E., Vallieres, E., Zhou, C., Wakelee, H., Bondarenko, I., Sakai, H., Saito, H., Ursol, G., Kawaguchi, K., Liu, Y., Levchenko, E., Kislov, N., Reck, M., Liersch, R., McNally, V.A., Zhu, Q., Ding, B., Bennett, E., Gitlitz, B., Altorki, N.K.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma
Hinkel, A, Tso, C L, Gitlitz, B J, Neagos, N, Schmid, I, Paik, S H, deKernion, J, Figlin, R, Belldegrun, A
Published in Journal of immunotherapy (1997) (01.01.2000)
Published in Journal of immunotherapy (1997) (01.01.2000)
Get more information
Journal Article
PL02.05 IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
Altorki, N., Felip, E., Zhou, C., Vallieres, E., Moiseyenko, V., Smolin, A., Rittmeyer, A., Vereshchako, R., Perol, M., Schutte, W., Fang, J., Tao, M., Teixeira, E., Kim, Y., Gitlitz, B., Bennett, E., Mcnally, V., Wu, F., Deng, Y., Wakelee, H.
Published in Journal of thoracic oncology (01.10.2021)
Published in Journal of thoracic oncology (01.10.2021)
Get full text
Journal Article